Should The Government Compensate Kidney Donation? by Alex Tabarrok, Foundation For Economic Education
It’s not a market, but is it better than prohibition?
The latest issue of the American Journal of Transplantation has an excellent and comprehensive cost-benefit analysis of paying kidney donors, by Held, McCormick, Ojo, and Roberts.
Earlier, Becker and Elias estimated that a payment of $15,000 per living donor would be sufficient to eliminate the US waiting list. The authors adopt a larger figure of $45,000 for living donors and $10,000 for deceased donors and find that even at these rates paying donors generates benefits far in excess of costs.
Baupost's investment process involves "never-ending" gleaning of facts to help support investment ideas Seth Klarman writes in his end-of-year letter to investors. In the letter, a copy of which ValueWalk has been able to review, the value investor describes the Baupost Group's process to identify ideas and answer the most critical questions about its potential Read More
In particular, a program of government compensation of kidney donors would provide the following bene?ts (quoting from the article):
- Transplant kidneys would be readily available to all patients who had a medical need for them, which would prevent 5,000 to 10,000 premature deaths each year and signi?cantly reduce the suffering of 100,000 more receiving dialysis.
- This would be particularly bene?cial to patients who are poor and African American because they are considerably over-represented on the transplant waiting list. Indeed, it would be a boon to poor kidney recipients because it would enable them to reap the great bene?ts of transplantation at very little expense to themselves.
- Because transplant candidates would no longer have to spend almost 5 years receiving dialysis while waiting for a transplant kidney, they would be younger and healthier when they receive their transplant, increasing the chances of a successful transplantation.
- With a large number of transplant kidneys available, it would be much easier to ensure the medical compatibility of donors and recipients, which would increase the success rate of transplantation.
- Taxpayers would save about $12 billion each year. Dialysis is not only an inferior therapy for end-stage renal disease (ESRD), it is also almost 4 times as expensive per quality-adjusted life-year (QALY) gained as a transplant.
About Alex Tabarrok
Alex Tabarrok is a professor of economics at George Mason University. He blogs at Marginal Revolution with Tyler Cowen.